Adriane M Zernhelt
Research Subjects
Adriane M Zernhelt has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Amita Patnaik
Institute of Cancer Research, Sutton, United Kingdom; Novartis Pharmaceuticals Corporation, Summit, NJ; Cancer Therapy and Research Centre, San Antonio, TX
1 shared publication - Andrea Biondo
Drug Development Unit, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
1 shared publication - Anthony William Tolcher
START, San Antonio, TX
1 shared publication - Daniel M. Sullivan
Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
1 shared publication - Eric Xueyu Chen
Princess Margaret Cancer Centre 4 Toronto, Ontario
1 shared publication - Ernestina Tetteh
Merck & Co., Inc., One Merck Drive, Whitehouse Station, NJ 08889, USA
1 shared publication
Latest Publications
- Open Access
- 3 January 2014
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 7 (1) , 1
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.
- 3 January 2014
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 7 (1) , 1
Open AccessPhase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.